RIS Rx's Real-Time Play to Plug Pharma’s $90 Billion Patient Aid Leak

IRVINE, CA – August 13, 2026 – In the pharmaceutical industry, the gap between a drug's list price and the actual revenue a manufacturer receives is a chasm known as the Gross-to-Net (GTN) bubble. Estimated to reach $356 billion this year, this gap is filled with rebates, chargebacks, and the soaring costs of patient affordability programs. But a significant portion of that money—an estimated $90 billion annually—simply leaks away, failing to reach its intended destination. Now, a healthcare technology firm is making a strategic maneuver that signals a new front in the war on this waste, combining real-time technology with expert human intervention to stanch the bleeding at its source.

RIS Rx, a firm founded by pharmacists, today announced a critical enhancement to its Affordability, Audit & Assurance (Triple A) platform. The system now monitors pharmacy claims in real time, flagging errors not after the money is gone, but at the moment of the transaction. This move from retrospective cleanup to pre-payment prevention represents a fundamental shift in how pharmaceutical companies can protect the integrity of their multi-billion-dollar patient support programs.

The Anatomy of a Leak: Deconstructing the GTN Chasm

For decades, managing GTN has been an exercise in financial forensics. Manufacturers would audit claims data months after the fact, trying to claw back funds lost to misprocessed claims. This leakage is particularly acute in patient copay assistance programs, where industry analysis suggests up to 20% of the financial support never reaches the intended patient. The causes are a complex mix of clerical errors, misunderstood program rules, and the intricate policies of Pharmacy Benefit Managers (PBMs), such as copay accumulator and maximizer programs that can divert manufacturer funds.

The result is a system where billions are spent on programs that are simultaneously a competitive necessity and a massive financial drain. For a patient, this inefficiency can mean their copay assistance runs out prematurely, creating an unexpected financial barrier to their medication. For a manufacturer, it’s a direct hit to the bottom line and a threat to the viability of the very programs designed to ensure market access.

Beyond the Alert: A New Model for Intervention

RIS Rx's strategic gambit is not merely about faster detection. While other solutions may offer alerts, the company argues that detection has never been the primary bottleneck. The true differentiator, they claim, is the follow-through.

“A real-time alert nobody follows-up on is just a faster way to watch money leave the program,” said Stephen Hom, Co-founder and EVP of RIS Rx. “Most solutions stop at a pass/fail message to the pharmacy. Our PharmD team picks up the phone, gets the claim corrected, and documents the change in behavior.”

This “PharmD-to-PharmD” engagement model is the core of their maneuver. Instead of an automated rejection that may or may not be understood by a busy pharmacy technician, RIS Rx deploys its team of pharmacists to engage in peer-to-peer conversations. They correct the specific claim in question and, more importantly, educate the pharmacy on the program rules to prevent future errors. It’s a deliberate fusion of high-tech surveillance with high-touch, expert intervention, designed to drive lasting behavioral change where the errors occur.

The system is designed to be vendor-agnostic, bolting onto a manufacturer's existing copay vendor ecosystem with a simple data use agreement. This focus on seamless integration, with implementation measured in weeks, removes significant barriers to adoption and signals a strategy built for rapid market penetration.

The Financial Reckoning: Quantifying the Impact

The distinction between a simple alert and active intervention shows up starkly in the financial results. According to the company, its Triple A platform has already delivered more than $110 million in cumulative cost avoidance for just two brands in the highly competitive GLP-1 category. In another case, a neurology brand saw its monthly copay spend cut in half—a reduction of roughly $21 million per month—within two months of implementing the solution.

The most telling data point, however, comes from a moment when the system was turned off. During a one-month pause in monitoring for one program, RIS Rx reported that misprocessed claims jumped by 51%. This figure serves as a powerful testament to the persistence of underlying systemic issues and the necessity of continuous, active management. It suggests that without a constant guiding hand, pharmacy behavior quickly reverts to the error-prone mean.

The Ripple Effect on Patient Access and Market Strategy

While the financial savings for manufacturers are compelling, the ultimate signal of this maneuver points toward a realignment of patient access strategy. By ensuring financial assistance is used correctly, the system directly reinforces the stability of these programs for patients.

“Stephen and I are pharmacists. We built Triple A because we watched affordability dollars leak out of programs one mishandled claim at a time,” said Gerard Rivera, Co-founder and CEO of RIS Rx. “And for a patient, these leaked dollars mean that their copay card runs out far earlier than expected.”

In an era of high-cost specialty drugs, a manufacturer's ability to run an efficient and effective patient support program is a critical competitive advantage. It ensures patients can start and stay on therapy, which is fundamental to commercial success. By plugging the leaks, RIS Rx is not just saving manufacturers money; it is preserving the integrity of a vital tool for market access. The solution operates within a complex regulatory framework governed by HIPAA and evolving CMS rules, and its focus on preventing waste and ensuring compliance positions it as a tool for de-risking these essential programs.

By providing manufacturers with performance report cards that quantify cost recoupment and avoidance, the platform introduces a new level of accountability into the opaque world of patient support. This transparency allows companies to treat patient assistance not as an uncontrollable expense, but as a strategic investment that can be measured, managed, and optimized.